Achieved Q4 2024 PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 million; full-year 2024 net product revenue totaled $25.4 ...
REYOBIQ™ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma ...
Eli Lilly (NYSE: LLY) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable ...
Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to ...
The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...
A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...
Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for ...
Ever-Growing USA on MSN5d
Retratutide: Eli Lilly’s Groundbreaking Drug for Obesity & DiabetesIn the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...
Noon, is tackling ALS and other neurological disorders with a bold, multi-targeted approach. Fueled by a personal encounter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback